Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of “Buy” by Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been given an average rating of “Buy” by the eight research firms that are presently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $71.40.

A number of analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on Tuesday, October 1st. Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a report on Monday, August 12th. Leerink Partners assumed coverage on Arcturus Therapeutics in a research note on Monday, August 12th. They set an “outperform” rating and a $70.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th.

Institutional Trading of Arcturus Therapeutics

A number of institutional investors have recently modified their holdings of ARCT. Russell Investments Group Ltd. acquired a new position in Arcturus Therapeutics in the first quarter valued at about $40,000. Quest Partners LLC raised its position in shares of Arcturus Therapeutics by 3,283.5% in the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 3,579 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Arcturus Therapeutics by 10.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock worth $152,000 after acquiring an additional 428 shares during the period. Public Employees Retirement System of Ohio boosted its position in shares of Arcturus Therapeutics by 63.8% during the 1st quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company’s stock worth $156,000 after acquiring an additional 1,800 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in Arcturus Therapeutics by 66.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 5,153 shares of the biotechnology company’s stock valued at $174,000 after acquiring an additional 2,064 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Stock Up 0.2 %

NASDAQ:ARCT opened at $20.97 on Friday. Arcturus Therapeutics has a 12-month low of $17.52 and a 12-month high of $45.00. The firm has a market capitalization of $564.76 million, a price-to-earnings ratio of -5.36 and a beta of 2.61. The stock’s 50 day moving average price is $21.02 and its two-hundred day moving average price is $25.57.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. The business had revenue of $49.86 million for the quarter, compared to analysts’ expectations of $21.00 million. During the same quarter in the prior year, the business earned ($1.98) EPS. Equities research analysts expect that Arcturus Therapeutics will post -2.6 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.